CARMEL, Ind., Oct. 29, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare technology company driving better health through impactful, innovative solutions, announced today its financial results for the third quarter ended September 30, 2024.
Financial Highlights – 2024 Fiscal Third Quarter
Year over Year – Q3 2024 vs. Q3 2023
Third Quarter 2024 vs. Second Quarter 2024
Recent Operational Highlights
Management Commentary
Dr. Deepika Vuppalanchi, CEO of Syra Health, said, "We are excited to report year-over-year growth of 42%. Our commitment to increasing revenue and improving profit margins is driven by our strong team and a track record of success stories. We are laser-focused on expanding our portfolio of high-revenue clients in high-margin business units by delivering compelling value propositions tailored to meet their specific needs. Looking ahead, we anticipate that our mental health product, Syrenity, will attract new customers in the robust national and global mental and behavioral health markets, further diversifying our revenue streams.
Additionally, our extensive cost-saving strategy has yielded significant reductions in expenses across the board with a 69% decrease in net loss quarter-over-quarter. With our strong revenue growth, a robust sales pipeline spanning both public and private sectors, effective cost optimization strategies, and a steadfast commitment to innovative solutions, we are confident in our growth trajectory. We are determined to achieve profitability in 2025 and capitalize on the exciting opportunities ahead."
Q3 2024 Financial Results
Revenue for the quarter ended September 30, 2024, was $2.3 million, compared to the $1.6 million reported in the third quarter of 2023. Strong growth was driven by Population Health which grew 36% year over year, and Healthcare Workforce, which increased 54% year over year.
Gross profit margin was 30% in the third quarter of 2024, compared to 35% the previous year, attributed to revenue recognition in the third quarter of 2023 from our first milestone-based digital health product, Syrabot. With maintenance and operations for this project continuing for an additional three years, we believe we are well-positioned for future growth as we expand our digital health offerings and optimize our revenue streams.
Total operating expenses for the third quarter of 2024 were $1.1 million compared to $0.9 million in the third quarter of 2023, an increase of 22.2%.
Net loss for the third quarter of 2024 was $(417,535) compared to $(354,376) in the third quarter of 2023.
Total Revenue in the third quarter of 2024 was $2.3 million representing a 14.4% increase compared to the second quarter of 2024.
Gross profit margin in the third quarter of 2024 was 29.7%, compared to 17.8% in the second quarter of 2024. The 1190-basis point increase in gross margins quarter-over-quarter was primarily driven by cost-saving initiatives and enhanced operational efficiency, achieved by adopting a lean approach and reducing redundancies.
Total operating expenses in the third quarter of 2024 decreased 37% to $1.1 million compared to $1.74 million in the second quarter of 2024 due to a strategic focus on streamlining our operations and optimizing our workforce with a determination to reduce our cost structure.
Net loss for the third quarter of 2024 was $(417,535), a decrease of 69% from the net loss of $(1.4 million) in the second quarter of 2023. This improvement was due to restructuring efforts that reduced redundancies and increased operational efficiencies, providing a solid foundation to support ongoing business operations.
Cash on hand on September 30, 2024, was $2.7 million.
Conference Call
Management will hold a conference call to discuss the fiscal year's financial results at 9:00 am ET on October 29, 2024.
Interested parties can listen via a live webcast, from the link available in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations/q3-2024-earnings-call.
A replay will be available after the call, in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations/q3-2024-earnings-call.
ABOUT SYRA HEALTH
Syra Health leads the charge in addressing the toughest challenges in healthcare, from behavioral and mental health to population health, digital transformation, health education, and workforce development. Our technology-driven solutions focus on prevention, accessibility, and affordability, ensuring that every patient and provider gets the support they need. We proudly partner with payers, providers, life sciences organizations, academic institutions, and government entities to advance healthcare and improve outcomes. Learn more about our mission and services at www.syrahealth.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
SYRA HEALTH CORP. | ||||||||
September 30, | December 31, | |||||||
2024 | 2023 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 2,697,459 | $ | 3,280,075 | ||||
Accounts receivable, net | 884,445 | 1,060,634 | ||||||
Accounts receivable related party | - | 50,614 | ||||||
Other current assets | 482,990 | 389,787 | ||||||
Total current assets | 4,064,894 | 4,781,110 | ||||||
Property and equipment, net | 34,625 | 78,974 | ||||||
Right-of-use asset | 325,491 | 63,199 | ||||||
Total assets | $ | 4,425,010 | $ | 4,923,283 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 212,931 | $ | 462,991 | ||||
Accrued expenses | 309,606 | 198,978 | ||||||
Deferred revenue | 6,108 | - | ||||||
Current portion of operating lease liability, related party | 108,939 | 63,199 | ||||||
Notes payable | 240,221 | 184,904 | ||||||
Total current liabilities | 877,805 | 910,072 | ||||||
Non-current portion of operating lease liability, related party | 216,552 | - | ||||||
Total liabilities | 1,094,357 | 910,072 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity (deficit): | ||||||||
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no | - | - | ||||||
Class A common stock, $0.001 par value, 100,000,000 shares | 8,974 | 5,588 | ||||||
Convertible class B common stock, $0.001 par value, 5,000,000 | 833 | 833 | ||||||
Additional paid-in capital | 11,640,642 | 9,071,745 | ||||||
Accumulated deficit | (8,319,796) | (5,064,955) | ||||||
Total stockholders' equity (deficit) | 3,330,653 | 4,013,211 | ||||||
Total liabilities and stockholders' equity (deficit) | $ | 4,425,010 | $ | 4,923,283 | ||||
SYRA HEALTH CORP. | ||||||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Net revenues | $ | 2,253,336 | $ | 1,581,344 | $ | 5,975,357 | $ | 3,748,943 | ||||||||
Cost of services | 1,585,038 | 1,026,803 | 4,777,765 | 2,919,087 | ||||||||||||
Gross profit | 668,298 | 554,541 | 1,197,592 | 829,856 | ||||||||||||
Operating expenses: | ||||||||||||||||
Salaries and benefits | 594,738 | 592,241 | 2,178,105 | 1,612,605 | ||||||||||||
Professional services | 153,803 | 58,875 | 489,839 | 424,379 | ||||||||||||
Research and development expenses | 34,821 | - | 590,263 | - | ||||||||||||
Selling, general and administrative expenses | 288,305 | 234,084 | 1,147,142 | 657,904 | ||||||||||||
Depreciation | 25,541 | 12,357 | 55,460 | 36,413 | ||||||||||||
Total operating expenses | 1,097,208 | 897,557 | 4,460,809 | 2,731,301 | ||||||||||||
Operating loss | (428,910) | (343,016) | (3,263,217) | (1,901,445) | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest income | 13,641 | 2,820 | 18,448 | 2,826 | ||||||||||||
Interest expense | (2,266) | (14,180) | (10,072) | (44,449) | ||||||||||||
Total other income (expense) | 11,375 | (11,360) | 8,376 | (41,623) | ||||||||||||
Net loss | $ | (417,535) | $ | (354,376) | $ | (3,254,841) | $ | (1,943,068) | ||||||||
Weighted average common shares | 7,264,768 | 4,360,426 | 6,789,209 | 4,380,267 | ||||||||||||
Net loss per common share - basic and | $ | (0.06) | $ | (0.08) | $ | (0.48) | $ | (0.44) | ||||||||
SYRA HEALTH CORP. | ||||||||
2024 | 2023 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (3,254,841) | $ | (1,943,068) | ||||
Adjustments to reconcile net loss to net cash used in operating | ||||||||
Depreciation | 55,460 | 36,413 | ||||||
Bad debt expense | - | 9,922 | ||||||
Common stock issued for services | 74,647 | - | ||||||
Non-cash lease expense | 63,199 | 90,162 | ||||||
Stock-based compensation, stock options | 28,486 | 3,669 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 176,189 | 136,324 | ||||||
Accounts receivable, related party | 50,614 | - | ||||||
Other current assets | 285,456 | 58,979 | ||||||
Accounts payable | (250,060) | 500,391 | ||||||
Accounts payable, related parties | - | 18,221 | ||||||
Deferred revenue | 6,108 | 141,644 | ||||||
Accrued expenses | 110,628 | 35,479 | ||||||
Operating lease liability | (63,199) | (90,162) | ||||||
Net cash used in operating activities | (2,717,313) | (1,002,026) | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Purchase of property and equipment | (11,111) | (15,251) | ||||||
Net cash used in investing activities | (11,111) | (15,251) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Proceeds from sale of common stock and exercise of warrants | 2,469,150 | - | ||||||
Payment of deferred offering costs | - | (589,059) | ||||||
Proceeds received from line of credit | - | 300,000 | ||||||
Repayments on line of credit | - | (750,397) | ||||||
Proceeds received from advances, related party | - | 1,295,010 | ||||||
Repayments on advances, related party | - | (678,611) | ||||||
Repayments on notes payable | (323,342) | - | ||||||
Proceeds received from convertible notes payable | - | 1,455,000 | ||||||
Net cash provided by financing activities | 2,145,808 | 1,031,943 | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | (582,616) | 14,666 | ||||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF | 3,280,075 | 3,344 | ||||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ | 2,697,459 | $ | 18,010 | ||||
SUPPLEMENTAL INFORMATION: | ||||||||
Interest paid | $ | 10,072 | $ | 28,533 | ||||
Income taxes paid | $ | - | $ | - | ||||
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
Initial recognition of right-of-use asset and lease liability | $ | 325,491 | $ | - | ||||
Prepaid asset financed with note payable | $ | 378,659 | $ | - | ||||
Contacts:
For Investor or Media Inquiries:
Priya Prasad
COO & CFO
Syra Health Corp.
463-345-8963
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.50 |
| Daily Change: | -0.24 -32.30 |
| Daily Volume: | 37,618,596 |
| Market Cap: | US$4.490M |
December 02, 2024 November 26, 2024 September 13, 2024 August 08, 2024 July 30, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
